People: Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$0.30 (+2.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Yea, Christopher 

Mr. Christopher M. Yea, Ph.D., is the Chief Development Officer of of the Company. since November 2015 and became our Chief Development Officer as of November 2016 in connection with the reverse acquisition transaction. Prior to joining us, he was the Chief Operating Officer at Vantia, Ltd. from its spin-out from Ferring Pharmaceuticals in 2008, until November 2015. Prior to the spin-out of Vantia, Dr. Yea led the Biology group and was responsible for transition of candidates into development at Ferring Pharmaceuticals. Following post-doctoral work he spent several years at Roussel-UCLAF and Hoechst Marion Roussel. Dr. Yea holds a B. Sc. and Ph.D. in Biochemistry from the University of Bristol, UK.

Basic Compensation

Total Annual Compensation, USD 640,833
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 183,105
Fiscal Year Total, USD 823,938

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --